American Journal of Obstetrics & Gynecology Mfm最新文献_第9页

Racial and ethnic differences in self-reported substance use and screening during prenatal care 产前护理中自我报告的物质使用和筛查的种族和民族差异。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2025.101660

Erica Holland MD, Naima T. Joseph MD, MPH, Christopher P. Salas-Wright PhD, MSW, Michele R. Hacker ScD, MSPH, Summer Sherburne Hawkins PhD, MS

引用次数: 0

Letter to the editor regarding “The preeclampsia and hypertension target treatment study: a multicenter prospective study to evaluate the effectiveness of the antihypertensive therapy based on maternal hemodynamic findings” 致编辑关于“子痫前期和高血压靶向治疗研究：一项基于母体血流动力学结果评估降压治疗有效性的多中心前瞻性研究”的信。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2025.101600

Marium Jawaid MBBS, Laiba Tanveer MBBS, Muhammad Maaz MBBS

引用次数: 0

The role of pravastatin in preventing preeclampsia in high-risk pregnant women: a meta-analysis with trial sequential analysis: a response 回复“关于普伐他汀预防高危孕妇先兆子痫作用的致编辑信：一项试验序列分析的meta分析”。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2024.101586

Henrique Provinciatto MD, Maria Esther Barbalho MD

引用次数: 0

Vaginal progesterone for prevention of preterm birth in women with a history of preterm birth regardless of cervical length: an argument against use 对有早产史的妇女使用阴道黄体酮预防早产（无论宫颈长度如何）：反对使用的理由。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2024.101571

Anthony Melendez Torres MD, Sarahn Wheeler MD, MHS

{"title":"Vaginal progesterone for prevention of preterm birth in women with a history of preterm birth regardless of cervical length: an argument against use","authors":"Anthony Melendez Torres MD, Sarahn Wheeler MD, MHS","doi":"10.1016/j.ajogmf.2024.101571","DOIUrl":"10.1016/j.ajogmf.2024.101571","url":null,"abstract":"<div><div>Preterm birth, defined as birth before 37 weeks of gestation, has a significant public health effect as the most frequent cause of neonatal-related death and the second most frequent cause of infant-related death at the age of <5 years. Given the unclear and likely multifactorial etiologic nature of preterm birth, interventions to address this condition remain elusive. Progesterone supplementation was once considered a promising strategy for reducing preterm birth among patients with a history of previous preterm birth. However, more recent data suggesting limited efficacy led the United States Food and Drug Administration to revoke approval of 17-alpha hydroxyprogesterone caproate. Vaginal progesterone supplementation remains controversial. Recently published meta-analyses evaluating large, preregistered randomized controlled trials with low risk of bias and selective outcome reporting have found that recurrent preterm birth rates are not significantly reduced by vaginal progesterone supplementation in patients with a singleton pregnancy and previous history of spontaneous preterm birth. Furthermore, studies reporting any benefit from vaginal progesterone in this patient population are noted to have smaller sample sizes, higher risk of bias and selective outcome reporting, and low external validity. Therefore, our study argues against the universal use of vaginal progesterone supplementation for the prevention of recurrent preterm birth.</div></div>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":"7 1","pages":"Article 101571"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of cervical cerclage after preterm premature rupture of membranes: an argument for retention 胎膜早破后宫颈环扎术的管理：主张保留宫颈：胎膜早破后保留宫颈环扎与去除宫颈环扎的对比。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2024.101569

Allen A. Ghareeb MD , Alisa Kachikis MD, MSc , Vy Nguyen BS , Amanda Roman MD, MPH

{"title":"Management of cervical cerclage after preterm premature rupture of membranes: an argument for retention","authors":"Allen A. Ghareeb MD , Alisa Kachikis MD, MSc , Vy Nguyen BS , Amanda Roman MD, MPH","doi":"10.1016/j.ajogmf.2024.101569","DOIUrl":"10.1016/j.ajogmf.2024.101569","url":null,"abstract":"<div><div>Preterm birth remains the leading cause of infant morbidity and mortality worldwide. Efforts aimed at reducing preterm birth rates have largely focused on mitigating risks in those who have already experienced a preterm delivery. Of note, 1 intervention, the placement of a cervical cerclage, has been shown to reduce the risk of subsequent preterm delivery in appropriate candidates. However, a cerclage does not mitigate the risk of preterm premature rupture of membranes. Preterm premature rupture of membranes is a significant contributor to the incidence of preterm births and can occur with a cerclage in place. Many studies have examined the outcomes associated with immediate vs delayed cerclage removal after preterm premature rupture of membranes with inconsistent results. This expert review summarized the characteristics of the studies examining the timing of cerclage removal after preterm premature rupture of membranes (Table 1) and current international guidelines (Table 2). In the absence of labor, infection, cervical laceration, or vaginal bleeding, it is recommended that cervical cerclage remains in situ after preterm premature rupture of membranes until 32 to 34 weeks of gestation.</div></div>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":"7 1","pages":"Article 101569"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nonsevere hypertensive disorders of pregnancy and oral antihypertensive medications: an argument against use 非严重妊娠高血压疾病与口服降压药：反对使用的论据。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2024.101560

Laurie B. Griffin MD, PhD , Rachel Sinkey MD , Alan Tita MD, PhD , Dwight J. Rouse MD, MSPH

{"title":"Nonsevere hypertensive disorders of pregnancy and oral antihypertensive medications: an argument against use","authors":"Laurie B. Griffin MD, PhD , Rachel Sinkey MD , Alan Tita MD, PhD , Dwight J. Rouse MD, MSPH","doi":"10.1016/j.ajogmf.2024.101560","DOIUrl":"10.1016/j.ajogmf.2024.101560","url":null,"abstract":"<div><div>Hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia, affect approximately 13% of all pregnancies and are a major cause of maternal and neonatal morbidity and mortality worldwide. Although the treatment of preeclampsia with severe features has been well established on the basis of randomized controlled data, international society guidelines vary on the treatment of gestational hypertension and preeclampsia without severe features. The American College of Obstetricians and Gynecologists recommends against the use of antihypertensive agents for nonsevere hypertension (blood pressure of <160/110 mm Hg) in both gestational hypertension and preeclampsia without severe features given a lack of level 1 evidence in support of treatment and the theoretical risk of masking of disease progression or causing adverse fetal effects, such as growth restriction. However, with the publication of the Chronic Hypertension in Pregnancy trial, (CHAP) which demonstrated the benefit of treatment of nonsevere chronic hypertension, “indication creep” or the application of a treatment outside the population of proven benefit is being observed with the use of antihypertensive medication for the treatment of nonsevere hypertension in gestational hypertension and preeclampsia without severe features. The use of antihypertensive treatment in this population without a definitive trial and no clearly defined safety protocols is potentially dangerous and could, at worst, lead to maternal and fetal harm or, at best, provide benefit in ways that are hard to assess and, thus, interfere with efforts to generate definitive evidence to change practice guidelines, denying many pregnant patients optimal care. It is imperative that a definitive trial be performed performed prior to the widespread use of antihypertensive treatment for gestational hypertension or preeclampsia without severe features.</div></div>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":"7 1","pages":"Article 101560"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

“Inpatient pharmacological thromboprophylaxis in the antepartum period: an argument for universal thromboprophylaxis” "产前住院病人的血栓预防药物治疗：普及血栓预防的论据"。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2024.101566

Julia Burd MD, Amanda Zofkie MD

{"title":"“Inpatient pharmacological thromboprophylaxis in the antepartum period: an argument for universal thromboprophylaxis”","authors":"Julia Burd MD, Amanda Zofkie MD","doi":"10.1016/j.ajogmf.2024.101566","DOIUrl":"10.1016/j.ajogmf.2024.101566","url":null,"abstract":"<div><div>Venous thromboembolism (VTE), a largely preventable condition, accounts for almost 15% of maternal mortalities. The physiologic changes of pregnancy, including quantitative changes in coagulation factors and compression of vasculature by the gravid uterus, cause an increase in risk of VTE, including deep vein thromboembolism (DVT), pulmonary embolism, and stroke (CVA). Long term antepartum admission for preeclampsia, preterm prelabor rupture of membranes (PPROM) or other high-risk pregnancy needs present additional risk factors for VTE due to the patient's medical condition and their inpatient status. Given the near-universal support for anticoagulation in patients with a history of venous thromboembolism or high-risk thrombophilia, we will focus this work on patients generally considered low or moderate risk. As outpatients, we do not recommend anticoagulation for this lower risk population. However, with the increase in risk factors for VTE with prolonged admission, it is our general practice to discuss the risks, benefits, and alternatives of chemical VTE prophylaxis 72 hours after admission and recommend administration to all patients unless they have active vaginal bleeding or are at risk for imminent delivery. Here, we will argue why this strategy of universal VTE prophylaxis during antepartum admission with unfractionated heparin (UFH) or low-molecular weight heparin (LMWH) is ultimately in the best interest of patient safety.</div></div>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":"7 1","pages":"Article 101566"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PPROM in the late preterm period: an argument for expectant management 早产晚期的早产儿猝死综合症：期待管理的论据。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2024.101563

Derek Lee MD, Tara A. Lynch MD, MS

{"title":"PPROM in the late preterm period: an argument for expectant management","authors":"Derek Lee MD, Tara A. Lynch MD, MS","doi":"10.1016/j.ajogmf.2024.101563","DOIUrl":"10.1016/j.ajogmf.2024.101563","url":null,"abstract":"<div><div>Preterm prelabor rupture of membranes (PPROM) is associated with significant neonatal risks. When PPROM occurs during the late preterm period (between 34 0/7 and 36 6/7 weeks gestation), the optimal gestational age for delivery is unclear and varies by regional practice. In 2020 the American College of Obstetrician and Gynecologists (ACOG) published guidelines indicating that both expectant management and immediate delivery were considered reasonable options. Historically, studies that examined the topic of expectant management versus immediate delivery of PPROM after 34 weeks supported immediate delivery based on an observed increased risk of infectious complications without any benefit to neonatal outcome. However, these studies were small and were underpowered to detect a meaningful difference in neonatal outcomes. In this review, we examine 6 randomized controlled trials and 2 meta-analyses of randomized controlled trials that investigated neonatal and maternal outcomes of expectant management versus immediate delivery of late preterm PROM. Included in this analysis are 3 recent randomized controlled trials (PPROMEXIL, PPROMEXIL2, and PPROMT) and 2 meta-analyses that demonstrate a decreased risk of respiratory distress syndrome and NICU admission rate with expectant management. This is counterbalanced by an increased risk of chorioamnionitis with expectant management, but definitions of chorioamnionitis are variable in the trials with unclear generalizability of the outcome across the trials. Additional analysis with a childhood outcome study showed no significant difference in neurodevelopment in infants born to expectant management of late preterm PROM, and an economic analysis found that expectant management was associated with lower delivery and neonatal costs. Overall, we support expectant management of late preterm PROM if maternal and fetal status are stable and there are no contraindications to expectant management but not extending beyond 37 0/7 weeks gestation.</div></div>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":"7 1","pages":"Article 101563"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increasing dialogue surrounding controversies in antepartum management among trainees 增加学员对产前管理争议的对话。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2025.101617

Sarah Boudova MD, PhD , Laurie Griffin MD, PhD , Carolina Martinez-King MD, MAS , John Soehl MD , Virginia Watkins MD , Tiffany Yang MD

引用次数: 0

Delivering insights through new perspectives, mentorship, and academic debate 通过新视角、导师指导和学术辩论提供见解。

IF 3.8 2区医学

American Journal of Obstetrics & Gynecology Mfm Pub Date : 2025-03-01 DOI: 10.1016/j.ajogmf.2025.101618

Emily S. Miller MD, MPH, Suneet P. Chauhan MD, Karin A. Fox MD, MEd, Adam K. Lewkowitz MD, MPHS, Tracy A. Manuck MD, MSCI, Molly J. Stout MD, MS, Terri-Ann Bennett MD, Vincenzo Berghella MD

引用次数: 0